1
|
Kim J, Byeon SK, Oglesbee D, Schultz MJ, Matern D, Pandey A. A multiplexed targeted method for profiling of serum gangliosides and glycosphingolipids: application to GM2-gangliosidosis. Anal Bioanal Chem 2024:10.1007/s00216-024-05487-3. [PMID: 39190143 DOI: 10.1007/s00216-024-05487-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2024] [Revised: 07/29/2024] [Accepted: 08/09/2024] [Indexed: 08/28/2024]
Abstract
The analysis of gangliosides and glycosphingolipids is crucial for understanding cellular membrane structure and function as well as to accurately diagnose certain inborn errors of metabolism. GM2-gangliosidosis represents a rare and fatal group of lysosomal storage disorders characterized by accumulation of GM2 gangliosides in various tissues and organs. These disorders arise due to deficiency or functional impairment of the β-hexosaminidase A or B enzymes, which are responsible for degradation of GM2 ganglioside. Deficient enzyme activity primarily leads to the accumulation of GM2 gangliosides within the lysosomes of cells. Accurate and rapid diagnostic methods that detect increased levels of GM2 gangliosides in patients with GM2-gangliosidosis can play a significant role in early diagnosis and appropriate treatment of this condition. To address this need, we developed a multiplexed liquid chromatography-tandem mass spectrometry method targeting 84 species of gangliosides and other glycosphingolipids involved in ganglioside metabolism. Reproducibility, linearity, extraction efficiency, and sample stability were evaluated and proof-of-concept data obtained from analysis of serum samples from confirmed cases of GM2-gangliosidosis. This method has the potential to simultaneously monitor the biosynthesis of gangliosides and the lysosomal catabolic pathway serving as a valuable tool for screening and diagnosing an important group of lysosomal storage disorders.
Collapse
Affiliation(s)
- Jinyong Kim
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
| | - Seul Kee Byeon
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
| | - Devin Oglesbee
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
| | - Matthew J Schultz
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
| | - Dietrich Matern
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
| | - Akhilesh Pandey
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
- Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
- Manipal Academy of Higher Education, Manipal, Karnataka, India.
| |
Collapse
|
2
|
Blondel A, Kraoua I, Marcelino C, Khrouf W, Schlemmer D, Ganne B, Caillaud C, Fernández-Eulate G, Turki IBY, Dauriat B, Bonnefont-Rousselot D, Nadjar Y, Lamari F. Plasma G M2 ganglioside potential biomarker for diagnosis, prognosis and disease monitoring of GM2-Gangliosidosis. Mol Genet Metab 2023; 138:106983. [PMID: 36709536 DOI: 10.1016/j.ymgme.2022.106983] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/22/2022] [Revised: 12/08/2022] [Accepted: 12/21/2022] [Indexed: 12/27/2022]
Abstract
GM2-Gangliosidosis are a group of inherited lysosomal storage pathologies characterized by a large accumulation of GM2 ganglioside in the lysosome. They are caused by mutation in HEXA or HEXB causing reduced or absent activity of a lysosomal β-hexosaminidase A, or mutation in GM2A causing defect in GM2 activator protein (GM2AP), an essential protein for the activity of the enzyme. Biochemical diagnosis relies on the measurement of β-hexosaminidases A and B activities, which is able to detect lysosomal enzyme deficiency but fails to identify defects in GM2AP. We developed a rapid, specific and sensitive liquid chromatography-mass spectrometry-based method to measure simultaneously GM1, GM2, GM3 and GD3 molecular species. Gangliosides were analysed in plasma from 19 patients with GM2-Gangliosidosis: Tay-Sachs (n = 9), Sandhoff (n = 9) and AB variant of GM2-Gangliosidosis (n = 1) and compared to 20 age-matched controls. Among patients, 12 have a late adult-juvenile-onset and 7 have an infantile early-onset of the disease. Plasma GM2 molecular species were increased in all GM2-Gangliosidosis patients (19/19), including the patient with GM2A mutation, compared to control individuals and compared to patients with different other lysosomal storage diseases. GM234:1 and GM234:1/GM334:1 ratio discriminated patients from controls with 100% sensitivity and specificity. GM234:1 and GM234:1/GM334:1 were higher in patients with early-onset compared to those with late-onset of the disease, suggesting a relationship with severity. Longitudinal analysis in one adult with Tay-Sachs disease over 9 years showed a positive correlation of GM234:1 and GM234:1/GM334:1 ratio with age at sampling. We propose that plasma GM2 34:1 and its ratio to GM3 34:1 could be sensitive and specific biochemical diagnostic biomarkers for GM2-Gangliosidosis including AB variant and could be useful as a first line diagnostic test and potential biomarkers for monitoring upcoming therapeutic efficacy.
Collapse
Affiliation(s)
- Amélie Blondel
- Metabolic Biochemistry Department, Neurometabolic unit, DMU Biogem, Pitié-Salpêtrière University Hospital, AP-HP, Sorbonne University, 75013 Paris, France
| | - Ichraf Kraoua
- University of Tunis El Manar, Faculty of Medicine of Tunis, Tunis, Tunisia; Neurology Department, LR18SP04, National Institute Mongi Ben Hamida of Neurology, Tunis, Tunisia
| | - Chloé Marcelino
- Metabolic Biochemistry Department, Neurometabolic unit, DMU Biogem, Pitié-Salpêtrière University Hospital, AP-HP, Sorbonne University, 75013 Paris, France
| | - Walid Khrouf
- Metabolic Biochemistry Department, Neurometabolic unit, DMU Biogem, Pitié-Salpêtrière University Hospital, AP-HP, Sorbonne University, 75013 Paris, France
| | - Dimitri Schlemmer
- Metabolic Biochemistry Department, Neurometabolic unit, DMU Biogem, Pitié-Salpêtrière University Hospital, AP-HP, Sorbonne University, 75013 Paris, France
| | - Benjamin Ganne
- Cytogenetic and Medical Genetic Department, Hôpital de la mère et de l'enfant, 87042 Limoges, France
| | - Catherine Caillaud
- Biochemistry, Metabolomics, and Proteomics Department, Necker Enfants Malades University Hospital, AP-HP, Center-Paris University, 75015 Paris, France
| | - Gorka Fernández-Eulate
- Neurology Department, Reference Center for Lysosomal Diseases, Pitié-Salpêtrière University Hospital, AP-HP Sorbonne University, 75013 Paris, France; Institut Necker-Enfants Malades, INSERM U1151, BioSPC (ED562), Université Paris Cité, Paris, France
| | - Ilhem Ben Youssef Turki
- University of Tunis El Manar, Faculty of Medicine of Tunis, Tunis, Tunisia; Neurology Department, LR18SP04, National Institute Mongi Ben Hamida of Neurology, Tunis, Tunisia
| | - Benjamin Dauriat
- Cytogenetic and Medical Genetic Department, Hôpital de la mère et de l'enfant, 87042 Limoges, France
| | - Dominique Bonnefont-Rousselot
- Metabolic Biochemistry Department, Neurometabolic unit, DMU Biogem, Pitié-Salpêtrière University Hospital, AP-HP, Sorbonne University, 75013 Paris, France; Paris University, UTCBS, U 1022 Inserm, UMR 88 CNRS, Paris, France
| | - Yann Nadjar
- Neurology Department, Reference Center for Lysosomal Diseases, Pitié-Salpêtrière University Hospital, AP-HP Sorbonne University, 75013 Paris, France
| | - Foudil Lamari
- Metabolic Biochemistry Department, Neurometabolic unit, DMU Biogem, Pitié-Salpêtrière University Hospital, AP-HP, Sorbonne University, 75013 Paris, France.
| |
Collapse
|
3
|
Alroy J, Adelman LS, Warren CD. Lectin histochemistry of gangliosidosis. II. Neurovisceral tissues from patients with Sandhoff's disease. Acta Neuropathol 1988; 76:359-65. [PMID: 3176901 DOI: 10.1007/bf00686972] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Lectin histochemical studies were performed on selected formalin-fixed, paraffin-embedded tissues of patients affected with the O variant of GM2-gangliosidosis (i.e., Sandhoff's disease). The purpose was to identify specific sugar residues of undegraded "stored" substances in cytoplasm of affected cells. We studied neural tissues from 13 patients, visceral tissues from four patients, and placentae from three affected fetuses. Neurons in all 13 cases studied stained with Concanavalia ensiformis agglutinin (Con A) and with Ulex europaeus agglutinin-I (UEA-I). Succinylated wheat germ agglutinin (S-WGA) stained affected visceral cells and astrocytes and macrophages in the central nervous system. These results demonstrate that alpha-D-mannosyl and alpha-L-fucosyl residues, which bind Con A and UEA-I, respectively, are present in affected neurons. Furthermore, they revealed the affected non-neuronal cells and astrocytes contain complex carbohydrates with nonreducing terminal beta-N-acetylglucosamine, which binds S-WGA.
Collapse
Affiliation(s)
- J Alroy
- Department of Pathology, Tufts University School of Medicine, Boston, MA 02111
| | | | | |
Collapse
|
4
|
Abstract
The gangliosidoses comprise an-ever increasing number of biochemically and phenotypically variant diseases. In most of them an autosomal recessive inherited deficiency of a lysosomal hydrolase results in the fatal accumulation of glucolipids (predominantly in the nervous tissue) and of oligosaccharides. The structure, substrate specificity, immunological properties of and genetic studies on the relevant glycosidases, ganglioside GM1 beta-galactosidase and beta-hexosaminidase isoenzymes, are reviewed in this paper. Contrary to general expectation, only a poor correlation is observed between the severity of the disease and residual activity of the defective enzyme when measured with synthetic or natural substrates in the presence of detergents. For the understanding of variant diseases and for their pre- and postnatal diagnosis, the necessity of studying the substrate specificity of normal and mutated enzymes under conditions similar to the in vivo situation, e.g., with natural substrates in the presence of appropriate activator proteins, is stressed. The possibility that detergents may have adverse affects on the substrate specificity of the enzymes is discussed for the beta-hexosaminidases. The significance of activator proteins for the proper interaction of lipid substrates and water-soluble hydrolases is illustrated by the fatal glycolipid storage resulting from an activator protein deficiency in the AB variant of GM2-gangliosidosis. Recent somatic complementation studies have revealed the existence of a presumably post-translational modification factor necessary for the expression of ganglioside GM1 beta-galactosidase activity. This factor is deficient in a group of variants of GM1-glangliosidosis. Among the possible reasons for the variability of enzyme activity levels in heterozygotes and patients, allelic mutations, formation of hybrid enzymes, and the existence of patients as compound heterozygotes are discussed. All these may result in the production of mutant enzymes with an altered specificity for a variety of natural substrates.
Collapse
|